BTIG Calls Palvella’s 21% FDA-Driven Drop a Buying Opportunity
The FDA denied Breakthrough Therapy status for QTORIN. BTIG analysts view the decision as a short-term setback and maintain their Buy rating with a $215 price target.
/ 4 items
#PVLA↓
Palvella Soars After Positive Phase 3 Data – First Approved Therapy for Microcystic LMs in Sight
Palvella Therapeutics shares surged 30% after strong Phase 3 SELVA trial data for QTORIN rapamycin gel in microcystic lymphatic malformations. First potential FDA-approved treatment could arrive in 2027.
FDA Grants Fast Track Status to New Skin Condition Treatment
Palvella Therapeutics (PVLA) receives FDA Fast Track designation for QTORIN rapamycin gel to treat angiokeratomas, a rare skin condition with no approved therapies affecting 50,000+ US patients.
Raymond James Boosts Palvella Therapeutics to Strong Buy Ahead of Key Phase 2 Data
Raymond James upgrades Palvella Therapeutics to Strong Buy with a new $143 price target, citing strong confidence in upcoming Phase 2 TOIVA readout for QTORIN rapamycin.